Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma

Affiliations

• ¹ Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain.
• ² Experimental Hematology, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
• ³ Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
• ⁴ Department of Haematology and Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark.
• ⁵ Statistics Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
• ⁶ Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.
• ⁷ Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
• ⁸ Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación Biomédica en Red de Cáncer, University of Salamanca, Salamanca, Spain.
• ⁹ Department of Hematology, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.
• ¹⁰ Department of Hematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
• ¹¹ Department of Hematology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
• ¹² Department of Hematology, Instituto Catalán de Oncología-Instituto de Investigación contra la Leucemia Josep Carreras-Hospital Germans Trias i Pujol, Barcelona, Spain.
• ¹³ Department of Hematology, St Vincent's Hospital, Melbourne, Australia.
• ¹⁴ Department of Hematology, Hospital La Paz, Madrid, Spain.
• ¹⁵ Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain.
• ¹⁶ Department of Hematology, University Hospital Fundación Jiménez Díaz, Madrid, Spain.
• ¹⁷ Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain.
• ¹⁸ Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
• ¹⁹ Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.